How tesamorelin works as a GHRH analog
One receptor, one signal
Tesamorelin is a GHRH analog, which means it binds the receptor that growth hormone-releasing hormone uses and prompts your pituitary to release your own growth hormone. Peppi's Tesamorelin pen holds 30 mg of tesamorelin in a ready-to-use, pre-filled pen, and a clinician licensed in your state reviews your intake before anything ships.
The plain answer to what is tesamorelin sits in its own FDA label, which describes it as the 44 amino acid sequence of human growth hormone-releasing factor plus a small six-carbon hexenoyl group.
Tesamorelin for visceral fat, ipamorelin only inside the CJC + Ipamorelin pen
Tesamorelin carries 26-week randomized trials in one population, and Peppi sells ipamorelin only inside the CJC + Ipamorelin pen.
- Visceral fat fell 15.2% on tesamorelin in a 26‑week HIV trial
- Ipamorelin raised growth hormone in a phase I study of healthy men
- No published human trial has measured ipamorelin's effect on muscle or fat
- Peppi's Tesamorelin pen holds 30 mg in one pre‑filled pen
of tesamorelin in each Tesamorelin pen
Ipamorelin: CJC + Ipamorelin pen only
Tesamorelin vs ipamorelin is less a contest than a goal question, because the two sit at different evidence levels and reach your pituitary by different routes.
| Feature | Tesamorelin | Ipamorelin |
|---|---|---|
| What it is | A 44 amino acid GHRH analog with a hexenoyl group | A five amino acid growth hormone secretagogue |
| Receptor it binds | The GHRH receptor on pituitary cells | The ghrelin receptor, called GHSR‑1a |
| Strongest human data | Two 26‑week randomized trials, plus one 12‑month trial | A phase I study in healthy men, plus one phase 2 trial after bowel surgery |
| FDA status | The brand form is approved only to reduce excess abdominal fat in adults with HIV lipodystrophy | No FDA‑approved drug product contains it |
| At Peppi | The Tesamorelin pen, 30 mg | Inside the CJC + Ipamorelin pen, 10 mg |
| Who sets the dose | A licensed clinician, from your intake | A licensed clinician, from your intake |
No published study has put the two side by side. A PubMed search in November 2026 for both names returned seven records, all of them reviews, so anyone searching ipamorelin vs tesamorelin is comparing two separate research files rather than one trial.
Quality is checkable either way. Your lot number is printed on the pen label, and Peppi's batch test results list potency, sterility, pH and endotoxins for that batch, tested by Accumark Labs and Atlas Analytics.
How ipamorelin works on the ghrelin receptor
A different doorway
Ipamorelin reaches the pituitary through the ghrelin receptor, GHSR-1a, the receptor the hunger hormone ghrelin uses. Same destination as tesamorelin, different doorway.
The ipamorelin peptide was described in 1998 by researchers at a Danish pharmaceutical company as a pentapeptide, a chain of five amino acids. In rat pituitary cells and in conscious swine it released growth hormone about as strongly as the older peptide GHRP-6, and in the swine it left FSH, LH, prolactin and TSH levels alone.
That paper's other finding is why ipamorelin kept being studied. Unlike GHRP-6 and GHRP-2, it did not raise ACTH or cortisol above the levels seen after GHRH. A 2026 review in Frontiers in Endocrinology reaches the same read of the human work, calling ipamorelin a relatively selective agonist of that receptor with comparatively little activation of other pituitary pathways.
Animal work also looked at the gut. In the ghrelin mimetic gut study, male rats had abdominal surgery and intestinal handling, which slowed stomach emptying, and intravenous ipamorelin sped it up again through that same ghrelin receptor route.
Set against that, the published ipamorelin benefits add up to this, by study type:
- A clear growth hormone rise in a phase I study of healthy men
- Little effect on other pituitary and adrenal hormones in those human reports
- Faster stomach emptying in rats after abdominal surgery
- No human trial has measured muscle or body fat, and in a 2001 mouse study ipamorelin raised body fat relative to body weight
Peppi does not sell ipamorelin on its own. It comes in one pen, paired with CJC-1295 (no DAC), which is covered further down.
Tesamorelin results for visceral fat
Deep fat, one population
Tesamorelin results in research mean less visceral fat, the deep fat packed around your organs. The large trials were run in adults with HIV who gained abdominal fat on antiretroviral therapy.
In a 2007 New England Journal of Medicine trial, 412 patients with HIV and abdominal fat gain, 86% of them men, took a daily injection of tesamorelin or placebo for 26 weeks. Visceral fat measured by CT scan fell 15.2% on tesamorelin and rose 5.0% on placebo. Triglycerides fell, IGF-1 rose 81.0%, and glucose measures did not differ between the groups.
The brand label reports both of its 26-week trials together. Mean visceral fat changed by -18% and -14% on tesamorelin against 2% and -2% on placebo, and mean lean body mass rose 1.3 kg and 1.2 kg while it fell slightly on placebo.
One trial ran outside HIV. In a 2012 Journal of Clinical Endocrinology and Metabolism study, 60 abdominally obese adults with reduced growth hormone secretion took tesamorelin or placebo for 12 months. Visceral fat fell 16 square centimeters on tesamorelin and rose 19 on placebo, with no change in fasting glucose, 2-hour glucose or HbA1c.
Anyone reading about tesamorelin for weight loss should read the label's own limitation. The EGRIFTA WR prescribing information says it is not indicated for weight loss management, because the effect is weight neutral. Its approved use is the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy. The same label says tesamorelin raises IGF-1, that glucose intolerance or diabetes may develop during treatment, and that joint pain and injection site reactions were among the reactions reported in more than 5% of patients.
Peppi's Tesamorelin and CJC + Ipamorelin pens are compounded prescription peptides and are not FDA-approved. Peppi's Tesamorelin pen is a compounded pen, not the brand-name drug, and its own page says research in otherwise healthy adults is limited.

Featured pen
Tesamorelin
30 mg of tesamorelin in a ready-to-use, pre-filled pen with a twist-to-dose selector. It is $449 one-time, or 50% off your first month by subscription, and it needs to be kept in the refrigerator.
Daniel M., a verified buyer, described it this way: "I had been doing the right things but still wasn't seeing much change around my waist. My friend recommended Tesamorelin from Peppi and I noticed my clothes started fitting better and I could actually see the progress. Having a clinician check in made it feel a lot more legit than things I'd tried before." That's one person's experience, not a typical result, and results vary.
Ipamorelin for sleep & recovery
What the sleep data shows
No published human trial has tested ipamorelin for sleep or for training recovery. What human research does show is that your own growth hormone is released around sleep onset, and in older men the release after sleep onset tracked with deep sleep.
A 2005 study in the journal Sleep recorded two nights of sleep in 10 healthy older men and 10 healthy postmenopausal women while sampling their blood through the night. Growth hormone came out both before and after sleep onset, and in the men the release after sleep onset tracked with delta activity, the brain wave pattern of deep sleep.
That link is the thinking behind pairing a growth hormone peptide with sleep and recovery goals, and it is where Peppi's CJC + Ipamorelin pen sits. One pen holds 10 mg of ipamorelin and 10 mg of CJC-1295 (no DAC), and its page is tagged as studied for muscle growth support, fat loss support, and sleep and recovery.
The 2026 Frontiers in Endocrinology review is careful about the pair, and so is Peppi's own page. CJC-1295 without DAC has no peer-reviewed human studies, so its effects are inferred from related peptides, and controlled evidence for the combination in healthy people stays limited. That is why a licensed clinician reads your history and goals first.
One rule shapes this choice before any evidence does. You can only be prescribed one growth hormone peptide at a time, so Tesamorelin and CJC + Ipamorelin are never prescribed together.
Tesamorelin dosage & ipamorelin dosage
Labels, not advice
Only one of these two has a current FDA label with a number on it, and that number belongs to a brand formulation and one population.
On tesamorelin dosage, the brand label sets 1.28 mg injected under the skin of the abdomen once daily, for adults with HIV-associated lipodystrophy. That same label says its two formulations are not substitutable, so the number does not even carry between two brand versions of the same drug.
There is no comparable answer on ipamorelin dosage, because no approved product contains ipamorelin. Peppi's CJC + Ipamorelin page states plainly that there is no established dose for healthy adults, and the 2026 review lists ipamorelin's human record as phase I studies plus its postoperative ileus development, with no efficacy data in growth hormone related metabolic indications. Dosing charts on forums are not labels.
What a pen fixes is the arithmetic. These are the facts a Peppi pen gives you instead of a chart:
- The Tesamorelin pen holds 30 mg of tesamorelin
- A twist-to-dose selector, with no reconstituting and no mixing
- One pen is a one-month supply, refilled every 28 days
- A licensed clinician sets your dose from your intake, usually within 24 hours
Peppi's own note on timing is worth hearing before you start. Peptide therapy is cumulative, and Peppi recommends patients commit 4 to 6 months for results to build.
Taking tesamorelin with ipamorelin
Why they stay apart
Peppi has no product that puts tesamorelin and ipamorelin in one pen, and no published trial has tested the pair in people.
A tesamorelin ipamorelin blend is not something Peppi offers in any form. The 2026 Frontiers in Endocrinology review says the practice of combining a GHRH analog with ipamorelin comes largely from anecdotal rationale in off-label fitness discussion, with limited controlled evidence in healthy people.
Peppi's rule is simpler than the research question. You can only be prescribed one growth hormone peptide at a time, so Tesamorelin and CJC + Ipamorelin are never prescribed together, and your clinician reviews which one, if either, fits your goals.
Tesamorelin may fit if
- Deep belly fat and body composition are the goal
- You want the peptide with randomized human trials behind it
- You can keep a pen in the refrigerator
- You are ready to give it 4 to 6 months
The CJC + Ipamorelin pen may fit if
- Muscle, sleep and recovery goals come first
- Two pathways in one pen appeals to you
- You accept that human evidence for this pair is limited
If your goal is energy, endurance or metabolism rather than either of those, Peppi's MOTS-c pen is the Performance option that fits. Not sure where you land? Peppi's peptide goal quiz starts from goals in your own words, from losing body fat to sleeping better and having more energy, and takes under 2 minutes.
Not sure which growth hormone peptide fits your goals?
Take the QuizWhichever pen the quiz points to, the path is the same. A clinician licensed in your state reviews your intake, a licensed U.S. compounding pharmacy fills the prescription, every batch is third-party lab tested, and if your prescription isn't approved, you get a 100% refund.
Questions about tesamorelin & ipamorelin
Frequently asked questions
Short answers on fat loss, stacking and sleep.
Is Ipamorelin or Tesamorelin Better for Fat Loss?
For deep belly fat, tesamorelin is the one with randomized human trials, all of them in adults with HIV or in abdominally obese adults with reduced growth hormone. No published human trial has measured what ipamorelin does to body fat. Neither peptide is approved for fat loss, and the tesamorelin label calls its effect weight neutral.
Can You Stack Tesamorelin With Ipamorelin?
No. You can only be prescribed one growth hormone peptide at a time, so Tesamorelin and CJC + Ipamorelin are never prescribed together, and Peppi sells no pen that holds both. A November 2026 PubMed search for the two names returned seven reviews and no trial of the pair. A licensed clinician weighs your goals and history and decides which one, if either, is appropriate.
Which Peptide Is Better for Sleep?
No trial has compared them for sleep, and no human trial has tested ipamorelin for sleep. The link is indirect: in a 2005 study of 20 healthy older adults, growth hormone release after sleep onset tracked with deep sleep brain activity in the men. Peppi's CJC + Ipamorelin pen is the one studied for sleep and recovery goals, and a licensed clinician determines whether it suits you.
These peptides are not FDA-approved and are dispensed only with a prescription.
Peptide guides from Peppi
Keep reading

















